Community Based Strategies for Early Detection of Melanoma

Sponsor
Cedars-Sinai Medical Center (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04799106
Collaborator
Stanford University (Other)
200
9.1

Study Details

Study Description

Brief Summary

The purpose of this study is to pilot the use of community education and digital dermatology to increase the early detection of curable melanomas.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: Community Based Strategies for Early Detection of Melanoma

Study Design

Study Type:
Observational
Anticipated Enrollment :
200 participants
Observational Model:
Cohort
Time Perspective:
Prospective
Official Title:
A Pilot Feasibility Study of Community Based Strategies for Early Detection of Melanoma
Anticipated Study Start Date :
May 1, 2022
Anticipated Primary Completion Date :
Dec 31, 2022
Anticipated Study Completion Date :
Feb 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Completion of self and partner skin examinations [3 months]

    Proportion of individuals recruited to those that follow through with the protocol

  2. Completion of self and partner skin examinations [6 months]

    Proportion of individuals recruited to those that follow through with the protocol

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
Yes
Inclusion Criteria:
  • 18 years and older

  • 1mm lesion thickness with ulceration (T2b) or >2mm lesion thickness (T3/T4)

  • Low socioeconomic status (SES) Non-Latinx White individuals (according to Yost's index SES level based on a principal components analysis)

  • Latinx individuals

  • Individual resides in semi-rural area, including zip codes within Antelope Valley in Southern California and Salinas in Northern California

  • Individual speaks and reads English or Spanish

  • Voluntary willingness and comprehension to consent

Exclusion Criteria:

Exclusion criteria is stage 0, I, IV, or unstaged diagnosis, or any individual who does not meet the above stated eligibility criteria will be excluded from the study.

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • Cedars-Sinai Medical Center
  • Stanford University

Investigators

  • Principal Investigator: Robert Haile, DrPH, MPH, Cedars-Sinai

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Robert Haile, Director, Cancer Research Center for Health Equity, Cedars-Sinai Medical Center
ClinicalTrials.gov Identifier:
NCT04799106
Other Study ID Numbers:
  • STUDY00001181
First Posted:
Mar 16, 2021
Last Update Posted:
Feb 10, 2022
Last Verified:
Feb 1, 2022
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of Feb 10, 2022